Medical Journal Call for Papers: Breast Cancer Outbreak and Screening

As a common disease, cancer is estimated that one third of people may be diagnosed with malignant tumors in their lifetime in the UK. Almost all of us have had the experience of a close friend or family member who has been diagnosed with cancer. Oncologists are very keen to change the course of cancer patients.

Oncology is a very clinically oriented specialty. Most of the working hours of the week are in direct contact with patients in the outpatient department, radiotherapy department and ward. In this post, InnovationForever will conduct some discussions on breast cancer and bring some inspiration to oncology students and researchers.

The current status of breast cancer

According to the Global Burden of Cancer 2020 Update, the number of new breast cancer patients in the world has reached 2.26 million, which has surpassed lung cancer to become the "world's largest cancer". In China, 416,000 new cases of breast cancer has occurred in 2020, accounting for 18.4% of the global incidence.

Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase encoded by the ERBB2 gene. With the emergence and widespread use of anti-HER2 drugs such as trastuzumab and patuximab, the prognosis of HER2-positive breast cancer patients has shown a very significant improvement. In recent years, TKI such as lapatinib and antibody-coupled drugs (ADCs) such as T-DMI have also been used in the treatment of HER2-positive breast cancer patients. Accurate detection and assessment of HER2 status is essential to determine the population that will benefit from anti-HER2 therapy.

On the other side of the rising number of diagnosed patients, the medical community has never stopped the research process on the screening, diagnosis and treatment link. Under the current system, doctors have reached a high level of consensus on the treatment of breast cancer, and as long as it is detected early, the cost of the entire treatment is only a few thousand, but the key is that we are unable to accurately screen each and every early stage breast cancer patient.

New Solutions to Breast Cancer Screening

Although there are many problems in the process of breast cancer screening and prevention, it is always inseparable from the two elements of "medical supply" and "medical quality". The current mainstream AI companies usually point to "supply" and "quality" when solving the problem of breast cancer screening and prevention, i.e., using AI to complete the auxiliary quality control and auxiliary diagnosis.

Real-time quality control of mammograms with AI can reduce invalid exams and improve image quality. Combined with auxiliary diagnostic tools, some enterprises can achieve a detection rate of more than 90%.

The existing screening rate of breast cancer population for women of age is about 20%-30%, and it is difficult to bypass AI to reach the same level of screening as cervical cancer in the future.

Medical AI cuts into the clinic

Although ultrasound and mammography can solve the problem of basic breast cancer screening, the final diagnosis needs to be made with the help of tumor biopsy if we want to more accurately determine the benign and malignant lesions.

During the two sessions of the National People's Congress this year, Yu Jinming, deputy to the National People's Congress, a member of the Chinese Academy of Engineering and president of Shandong Cancer Hospital, suggested that cervical cancer, breast cancer and other gynecological tumor screening be included in medical insurance. Throughout the industry, high-quality breast cancer AI screening technology has been shaped by several enterprises, only that it always takes some time for a cutting-edge technology to go from the laboratory to every corner of medical treatment.

Before submitting your manuscript to the Journal of Modern Medical Oncology (JMMO, ISSN 2708-0005), please familiarize yourself with our journal's formatting requirements and ethics policy. If you have additional questions about policies, manuscript fees, or review, please feel free to contact us at editorial.office@innovationforever.com.

Our website: https ://www.innovationforever.com.